Mirae Asset Global Investments Co. Ltd. Has $3.90 Million Stock Position in Insulet Co. (NASDAQ:PODD)

Mirae Asset Global Investments Co. Ltd. boosted its holdings in Insulet Co. (NASDAQ:PODD) by 11.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,810 shares of the medical instruments supplier’s stock after purchasing an additional 1,712 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Insulet were worth $3,900,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in PODD. Blue Trust Inc. boosted its position in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares in the last quarter. International Assets Investment Management LLC acquired a new position in Insulet during the 2nd quarter worth approximately $32,000. UMB Bank n.a. boosted its holdings in Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 81 shares in the last quarter. CVA Family Office LLC grew its stake in Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares during the period. Finally, Massmutual Trust Co. FSB ADV increased its holdings in shares of Insulet by 159.2% during the second quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 156 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Raymond James increased their target price on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. UBS Group lifted their price objective on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Canaccord Genuity Group upped their target price on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Citigroup lifted their price target on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Finally, Piper Sandler increased their price objective on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $242.29.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $232.37 on Wednesday. The company has a market capitalization of $16.29 billion, a P/E ratio of 42.25, a price-to-earnings-growth ratio of 4.36 and a beta of 1.21. The company’s 50-day moving average is $224.27 and its 200 day moving average is $200.35. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. Insulet Co. has a fifty-two week low of $128.68 and a fifty-two week high of $243.98.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The company had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. During the same period in the prior year, the firm posted $0.38 EPS. The business’s revenue was up 23.2% on a year-over-year basis. On average, equities research analysts forecast that Insulet Co. will post 3.04 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.